{"id":2299,"date":"2020-11-25T00:00:00","date_gmt":"2020-11-25T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2299"},"modified":"2020-11-25T00:00:00","modified_gmt":"2020-11-25T00:00:00","slug":"centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/","title":{"rendered":"CENTOGENE rozszerza wsp\u00f3\u0142prac\u0119 z PTC Therapeutics, aby uzyska\u0107 nowe informacje na temat niedoboru dekarboksylazy aromatycznych L-aminokwas\u00f3w (AADC)"},"content":{"rendered":"

Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries<\/p>\n

CAMBRIDGE, Mass. and Rostock and Heidelberg, Germany and BERLIN, November 25, 2020 (GLOBE NEWSWIRE) \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has expanded its partnership with PTC Therapeutics, Inc. The companies will work together in several new regions including many countries in Europe, the Middle East, and Latin America to provide genetic testing and 3-O-Methyldopa (3-OMD) biomarker analytics to help identify patients with Aromatic L-amino Acid Decarboxylase (AADC) deficiency. AADC deficiency is a life-shortening, ultra-rare genetic disorder that causes severe disability and ongoing physical and mental suffering from the first few months of life. In addition, CENTOGENE will now provide this testing and biomarker analytics for patients involved in the REVEAL CP study, a screening study designed to determine the prevalence of AADC deficiency in patients with cerebral palsy (CP) of unknown cause.<\/p>\n

The REVEAL CP study will screen patients for AADC deficiency with CentoCard\u00ae \u2013 CENTOGENE\u2019s CE-labeled dried blood spot collection kit \u2013 by evaluating blood samples for above normal levels of 3-OMD. Patients with elevated 3-OMD will be further tested for decreased levels of AADC enzyme activity and the presence of variants in the DOPA decarboxylase (DDC) gene. Through the generation of insights from the study, CENTOGENE and PTC aim to shorten the diagnosis time for patients living with AADC deficiency and ultimately accelerate the discovery of potential treatment options for patients living with this rare genetic disorder.<\/p>\n

Justin Bingham, CENTOGENE\u2019s Senior Vice President of Business Development, stated, \u201cWe are pleased to expand our partnership with PTC to support the REVEAL CP study, a global screening study designed to determine the prevalence of AADC deficiency in patients with cerebral palsy of an unknown cause. Together, we will offer genetic testing and 3-OMD biomarker analytics and widen the geographical scope of the no cost testing program, all of which are critical steps as we work together to bring hope to patients living with this rare genetic disorder.\u201d<\/p>\n

\u201cPTC is proud to continue and expand our partnership with CENTOGENE. We believe the insights we expect to gain from this genetic testing program may help physicians diagnose patients with AADC deficiency,\u201d said Claudio Santos, Senior Vice President of Global Medical Affairs at PTC Therapeutics. \u201cThe AADC deficiency diagnostic testing program and REVEAL CP study are critical ways in which we can help to shorten the diagnostic journey that so many patients and families face. This is central to our mission and daily commitment at PTC to help patients with rare disorders.\u201d<\/p>\n

CENTOGENE and PTC began collaborating in 2019 to create a diagnostic program for AADC deficiency, a rare inherited disorder that affects the way signals are passed between certain cells in the nervous system. AADC deficiency causes severe developmental disabilities, the inability to develop any motor strength and control, frequent hospitalizations, and the need for life-long care. At this time, there is no cure for AADC deficiency.<\/p>\n

The testing is provided at no cost to patients and can be accessed via CENTOGENE\u2019s user-friendly CentoPortal\u00ae platform (www.centoportal.com<\/a>), or alternatively by sending an email to AADCdtesting@ptcbio.com<\/a>. To learn more about the REVEAL CP study email medinfo@ptcbio.com<\/a>.<\/p>\n

O firmie CENTOGENE<\/h2>\n

CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne i genetyczne w praktyczne informacje dla pacjent\u00f3w, lekarzy i firm farmaceutycznych. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych, wykorzystuj\u0105c nasz\u0105 rozleg\u0142\u0105 wiedz\u0119 na temat chor\u00f3b rzadkich, w tym dane epidemiologiczne i kliniczne, a tak\u017ce innowacyjne biomarkery. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 chor\u00f3b rzadkich opart\u0105 na naszym repozytorium danych z rzeczywistego \u015bwiata, obejmuj\u0105cym ponad 3,6 miliarda wa\u017conych punkt\u00f3w danych od oko\u0142o 570 000 pacjent\u00f3w z ponad 120 kraj\u00f3w (stan na 31 sierpnia 2020 r.).<\/p>\n

Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi tych pacjent\u00f3w. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma, kt\u00f3ra kompleksowo analizuje dane wielopoziomowe w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych, co mo\u017ce pom\u00f3c w identyfikacji pacjent\u00f3w i usprawni\u0107 wprowadzanie lek\u00f3w sierocych na rynek przez naszych partner\u00f3w farmaceutycznych. Na dzie\u0144 31 sierpnia 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z ponad 40 partnerami farmaceutycznymi, obejmuj\u0105cymi ponad 45 r\u00f3\u017cnych chor\u00f3b rzadkich.<\/p>\n

Kontakt dla medi\u00f3w:<\/h5>\n

CENTOGENE
Sun Kim
Dyrektor ds. strategii i relacji inwestorskich
investor.relations@centogene.com <\/a><\/p>\n

Doradztwo FTI
Bridie Lawlor
+1.917.929.5684
bridie.lawlor@fticonsulting.com<\/a><\/p>\n

Wa\u017cna informacja i wy\u0142\u0105czenie odpowiedzialno\u015bci <\/strong><\/h5>\n

Niniejsza informacja prasowa zawiera stwierdzenia stanowi\u0105ce \u201cstwierdzenia dotycz\u0105ce przysz\u0142o\u015bci\u201d zgodnie z definicj\u0105 tego terminu zawart\u0105 w ameryka\u0144skiej ustawie o reformie przepis\u00f3w procesowych dotycz\u0105cych papier\u00f3w warto\u015bciowych z 1995 r. (Private Securities Litigation Reform Act of 1995), w tym stwierdzenia wyra\u017caj\u0105ce opinie, oczekiwania, przekonania, plany, cele, za\u0142o\u017cenia lub prognozy Sp\u00f3\u0142ki dotycz\u0105ce przysz\u0142ych zdarze\u0144 lub wynik\u00f3w, w przeciwie\u0144stwie do stwierdze\u0144 odzwierciedlaj\u0105cych fakty historyczne. Przyk\u0142adami s\u0105 om\u00f3wienia naszych strategii, plan\u00f3w finansowania, mo\u017cliwo\u015bci rozwoju i wzrostu rynku. W niekt\u00f3rych przypadkach takie stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci mo\u017cna zidentyfikowa\u0107 po terminologii, takiej jak \u201cprzewidywa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cwierzy\u0107\u201d, \u201cszacowa\u0107\u201d, \u201cplanowa\u0107\u201d, \u201cd\u0105\u017cy\u0107\u201d, \u201cprognozowa\u0107\u201d lub \u201coczekiwa\u0107\u201d, \u201cmo\u017ce\u201d, \u201cb\u0119dzie\u201d, \u201cby\u0142by\u201d, \u201cm\u00f3g\u0142by\u201d lub \u201cpowinien\u201d \u2013 formy przecz\u0105ce tych termin\u00f3w lub podobne. Stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci oparte s\u0105 na aktualnych przekonaniach i za\u0142o\u017ceniach kierownictwa oraz na informacjach, do kt\u00f3rych Sp\u00f3\u0142ka ma obecnie dost\u0119p. Jednak\u017ce te stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci nie stanowi\u0105 gwarancji naszych wynik\u00f3w i nie nale\u017cy na nich nadmiernie polega\u0107. O\u015bwiadczenia prognostyczne podlegaj\u0105 wielu czynnikom ryzyka, niepewno\u015bci i innym zmiennym okoliczno\u015bciom, takim jak niekorzystne warunki gospodarcze na \u015bwiecie oraz ci\u0105g\u0142a niestabilno\u015b\u0107 i zmienno\u015b\u0107 na \u015bwiatowych rynkach finansowych, wp\u0142yw pandemii COVID-19 na nasz\u0105 dzia\u0142alno\u015b\u0107 i wyniki operacyjne, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i polityce rz\u0105dowej, presja wynikaj\u0105ca z rosn\u0105cej konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zana z zatwierdzeniem regulacyjnym, w tym przez Ameryka\u0144sk\u0105 Agencj\u0119 ds. \u017bywno\u015bci i Lek\u00f3w (FDA), nasze uzale\u017cnienie od podmiot\u00f3w zewn\u0119trznych i partner\u00f3w, w tym nasza zdolno\u015b\u0107 do zarz\u0105dzania wzrostem i nawi\u0105zywania nowych relacji z klientami, nasza zale\u017cno\u015b\u0107 od bran\u017cy chor\u00f3b rzadkich, nasza zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasza zale\u017cno\u015b\u0107 od kluczowego personelu, nasza zale\u017cno\u015b\u0107 od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych lub innych czynnik\u00f3w. Takie ryzyka i niepewno\u015bci mog\u0105 spowodowa\u0107, \u017ce o\u015bwiadczenia b\u0119d\u0105 niedok\u0142adne, a czytelnik\u00f3w ostrzega si\u0119 przed nadmiernym poleganiem na takich o\u015bwiadczeniach. Wiele z tych ryzyk jest poza kontrol\u0105 Sp\u00f3\u0142ki i mo\u017ce spowodowa\u0107, \u017ce jej rzeczywiste wyniki b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od tych, kt\u00f3rych si\u0119 spodziewa\u0142a. O\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym s\u0105 aktualne wy\u0142\u0105cznie na dzie\u0144 jego publikacji. Sp\u00f3\u0142ka nie zobowi\u0105zuje si\u0119, a w szczeg\u00f3lno\u015bci nie zobowi\u0105zuje si\u0119 do aktualizacji takich o\u015bwiadcze\u0144 ani do publicznego og\u0142aszania skutk\u00f3w jakichkolwiek zmian w tych o\u015bwiadczeniach w celu odzwierciedlenia przysz\u0142ych zdarze\u0144 lub wydarze\u0144, z wyj\u0105tkiem przypadk\u00f3w wymaganych przez prawo.<\/p>\n

Aby uzyska\u0107 wi\u0119cej informacji, prosimy zapozna\u0107 si\u0119 z sekcj\u0105 \u201eCzynniki ryzyka\u201d w naszym Raporcie Rocznym za rok obrotowy zako\u0144czony 31 grudnia 2019 r. na Formularzu 20-F z\u0142o\u017conym w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) 23 kwietnia 2020 r., Formularzu 6-K zawieraj\u0105cym nasze wyniki finansowe za trzy miesi\u0105ce zako\u0144czone 31 marca 2020 r., z\u0142o\u017conym w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) 15 czerwca 2020 r., a tak\u017ce z innymi bie\u017c\u0105cymi raportami i dokumentami z\u0142o\u017conymi w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC). Dokumenty te mo\u017cna uzyska\u0107 na stronie EDGAR. na stronie internetowej SEC.<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2299","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nCENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-25T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency\",\"datePublished\":\"2020-11-25T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/\"},\"wordCount\":1241,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/\",\"name\":\"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-11-25T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency | CENTOGENE","og_description":"Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing […]","og_url":"https:\/\/www.centogene.com\/pl\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/","og_site_name":"CENTOGENE","article_published_time":"2020-11-25T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"6 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency","datePublished":"2020-11-25T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/"},"wordCount":1241,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/","url":"https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/","name":"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-11-25T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-expands-partnership-with-ptc-therapeutics-to-generate-new-insights-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2299"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2299\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}